Bio-Path (BPTH) Competitors $0.13 +0.00 (+1.77%) As of 02:28 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. VIVS, GLTO, INM, CPHI, XBIO, CMND, ALBT, DRMA, INDP, and JAGXShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include VivoSim Labs (VIVS), Galecto (GLTO), InMed Pharmaceuticals (INM), China Pharma (CPHI), Xenetic Biosciences (XBIO), Clearmind Medicine (CMND), Avalon GloboCare (ALBT), Dermata Therapeutics (DRMA), Indaptus Therapeutics (INDP), and Jaguar Animal Health (JAGX). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. Its Competitors VivoSim Labs Galecto InMed Pharmaceuticals China Pharma Xenetic Biosciences Clearmind Medicine Avalon GloboCare Dermata Therapeutics Indaptus Therapeutics Jaguar Animal Health VivoSim Labs (NASDAQ:VIVS) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability. Does the media prefer VIVS or BPTH? In the previous week, VivoSim Labs had 5 more articles in the media than Bio-Path. MarketBeat recorded 7 mentions for VivoSim Labs and 2 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.50 beat VivoSim Labs' score of 0.45 indicating that Bio-Path is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VivoSim Labs 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bio-Path 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is VIVS or BPTH more profitable? Bio-Path has a net margin of 0.00% compared to VivoSim Labs' net margin of -1,396.48%. VivoSim Labs' return on equity of -32.95% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets VivoSim Labs-1,396.48% -32.95% -21.31% Bio-Path N/A -2,842.40%-337.48% Which has more volatility and risk, VIVS or BPTH? VivoSim Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Do institutionals & insiders hold more shares of VIVS or BPTH? 8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 3.7% of VivoSim Labs shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation and earnings, VIVS or BPTH? VivoSim Labs has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVivoSim Labs$140K32.70-$2.48M-$10.20-0.17Bio-PathN/AN/A-$16.08MN/AN/A SummaryVivoSim Labs beats Bio-Path on 8 of the 10 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.10M$822.68M$5.72B$9.77BDividend YieldN/A4.84%3.77%4.10%P/E RatioN/A1.1830.9025.26Price / SalesN/A25.65403.8188.28Price / CashN/A19.5625.2228.45Price / Book0.196.599.516.00Net Income-$16.08M-$4.67M$3.26B$265.34M7 Day Performance-5.36%1.41%4.48%2.84%1 Month Performance-15.06%0.94%5.19%1.58%1 Year Performance-91.05%15.34%31.75%25.40% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path1.4669 of 5 stars$0.13+1.8%N/A-91.2%$1.10MN/A0.0010VIVSVivoSim LabsN/A$1.78+2.0%N/AN/A$4.54M$140K-0.1720Earnings ReportGap UpGLTOGalecto3.7976 of 5 stars$3.33-1.5%$10.00+200.4%-76.5%$4.48MN/A-0.2540Short Interest ↓INMInMed Pharmaceuticals1.33 of 5 stars$2.25+0.4%N/A-17.4%$4.48M$4.60M-0.1910Short Interest ↓CPHIChina Pharma0.7777 of 5 stars$1.35-9.1%N/A-92.8%$4.40M$4.30M0.00250Gap UpXBIOXenetic Biosciences1.1437 of 5 stars$2.74-1.1%N/A-12.3%$4.27M$2.50M-1.154Earnings ReportShort Interest ↑Analyst RevisionCMNDClearmind Medicine1.0451 of 5 stars$1.00+1.3%N/A-9.6%$4.21MN/A-0.91N/AShort Interest ↓ALBTAvalon GloboCare1.2009 of 5 stars$2.23+0.5%N/A-54.4%$4.20M$1.33M-0.115Earnings ReportShort Interest ↑DRMADermata Therapeutics3.3478 of 5 stars$6.16-4.6%$30.00+387.0%-69.5%$4.12MN/A-0.388Earnings ReportINDPIndaptus Therapeutics3.2226 of 5 stars$7.80+8.8%$238.00+2,951.3%-83.4%$4.10MN/A-0.196Earnings ReportJAGXJaguar Animal Health2.0203 of 5 stars$2.17+1.4%$60.00+2,665.0%-93.4%$4.10M$11.69M0.0050Earnings Report Related Companies and Tools Related Companies VIVS Alternatives GLTO Alternatives INM Alternatives CPHI Alternatives XBIO Alternatives CMND Alternatives ALBT Alternatives DRMA Alternatives INDP Alternatives JAGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access